These findings suggested that IL20RA activated JAK1-STAT3 to promote the stemness of breast cancer cells and that targeting IL20RA+ cells may be a promising strategy to reduce the stemness properties and decrease the chemoresistance of breast cancer cells. Here, JAK1 is linked to breast carcinoma.